Patent ID: 9012151
Filing Date: 2015-04-21
Classification: G01N

Abstract:
1. A method for the in vitro diagnosis or risk stratification of an adverse event in post-myocardial infarction patients, comprising a) determining the level of MR-proADM (SEQ ID NO: 2) in at least one blood specimen from a post-myocardial infarction patient using an immunoassay and an antibody specific for MR-proADM (SEQ ID NO: 2), and b) diagnosing or stratifying the risk of an adverse event in said post-myocardial infarction patient based on the result in a), wherein a level of MR-proADM (SEQ ID NO: 2) of greater than 0.73 nmol/L in said specimen correlates with a greater risk of death of or heart failure in said post-myocardial infarction patient.